Aurinia Pharmaceuticals acquires Kezar Life Sciences

Aurinia Pharma U.S., Inc. has acquired Kezar Life Sciences, Inc. for approximately $51 million. The acquisition, executed through a tender offer, involves a cash payment of $6.955 per share along with the provision of a contingent value right (CVR) for each share. The merger was completed efficiently without requiring a shareholder vote, adhering to Delaware law under Section 251(h) of the DGCL. Trading of Kezar shares ceased prior to the market's opening on May 11, 2026.

The tender offer expired at midnight on May 8, 2026. Following this, Aurinia Pharma accepted all validly tendered shares, completing the merger by May 11, 2026. Kezar now operates as a wholly owned subsidiary of Aurinia. All outstanding Kezar shares were converted into the cash consideration and CVR promised to shareholders. The transaction met the necessary conditions, achieving over 80% acceptance from Kezar shareholders.

Strategically, the acquisition enables Aurinia Pharma to expand its portfolio and strengthen its position in the biopharmaceutical sector. By securing Kezar, Aurinia gains access to the latter's pipeline and research capabilities, which aligns with its objectives to enhance therapeutic developments.

In the broader market context, this acquisition reflects ongoing consolidation in the biotechnology industry, where established firms like Aurinia aim to acquire niche companies with promising therapeutic research. For competitors, the deal reiterates the importance of strategic acquisitions in maintaining competitiveness and innovation in drug development pipelines.

Looking forward, delisting and deregistration procedures for Kezar are anticipated, although specific timelines for these steps have not been disclosed. Aurinia will also address any appraisal and tax withholding issues as per the merger and CVR Agreement. This transaction highlights the tactical adjustments being made by players within the sector to capitalize on emerging market opportunities and therapeutic innovations.